A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Key Inclusion Criteria:

• The participant has a diagnosis of migraine as defined by InternationalClassification of Headache Disorders Third Edition (ICHD-3) guidelines confirmed atthe Screening Visit.

• The participant has a history of migraine onset ≥ 12 months prior to the ScreeningVisit.

• The participant has a migraine onset at ≤50 years of age.

• The participant has ≥4 migraine days per month for each month within the past 3months prior to the Screening Visit.

• The participant has documented evidence of treatment failure in the past 10 years ofat least 1 to 4 (maximum) different migraine preventive medications.

Key Exclusion Criteria:

• The participant has previously been dosed with an anti-pituitary adenylatecyclase-activating peptide (anti-PACAP treatment).

• The participant has confounding and clinically significant pain syndromes.

• The participant has a diagnosis of acute or active temporomandibular disorder.

• The participant has a history or diagnosis of confounding headaches.

Additional protocol-defined criteria apply.